Recent

% | $
Quotes you view appear here for quick access.

Yippy, Inc. Message Board

garysnoop1 187 posts  |  Last Activity: Aug 14, 2016 8:17 AM Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Inovio completed end-of-Phase 2 meetings with both the FDA and European Medicines Agency (EMA) back in April, with both agencies discussing the development plan of the firm’s pipeline drug, VGX-3100, a therapeutic synthetic DNA vaccine treatment targeting cervical dysplasia caused by the human papillomavirus (HPV). Aschoff finds Inovio “on track” to initiate a Phase 3 trial in its fourth quarter following affirmative opinions from the FDA and EMA on the pipeline.

    INO’s commercial design for the intramuscular immunotherapy delivery to be administered for the Phase 3 trial has been finalized, with the firm to reveal the official design plans at initiation. Aschoff notes that Inovio’s fourth quarter will include several clinical read-outs that will prove significant, from its multi-center Phase 1 Zika virus vaccine (GLS-5700) trial, designed to treat the major ongoing epidemic in North and South America causing devastating birth defects. Interim immune response and safety data for the vaccine will be forthcoming. Additionally due for fourth-quarter are results for INO-3112, in Phase 1 to test HPV immunotherapy in head and neck cancer.

    The analyst notes, “Inovio and GeneOne Life Science completed enrollment of 75 healthy volunteers in the Phase 1 trial of their GLS-5300 MERS vaccine, with interim data expected in 4Q16. Interim results are also expected in 4Q16 from the Phase 1 trial of INO-5150 for prostate cancer targeting PSMA and PSA, now fully enrolled. Inovio ended 2Q16 with $134.5 million in cash, which should be sufficient to support its operations into 2018, including the $80 million in costs associated with the Phase 3 trial of VGX-3100.”

    Overall, Aschoff remains bullish on Inovio’s clinical progress. Looking into the next quarter, the analyst believes, “We expect Inovio to combine this newly acquired technology with its current electroporation devices and optimize its delivery device in the long run.”

  • garysnoop1 by garysnoop1 Aug 11, 2016 8:58 AM Flag

    Rodman & Renshaw’s Ram Selvaraju weighed in on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), after the company reported second-quarter results. With pipeline drug approval within reach, a new Phase 3 study starting soon, and a strategy bolstered by three drug candidates, Selvaraju reiterates a Buy on INO with a $17 price target, marking a nearly 93% increase from where the stock is currently trading.

    Worthy of note, management has discussed the affirmative path provided by both the FDA and the European Medicines Agency (EMA) for its pipeline drug VGX-3100 to treat HPV-16/18-related high grade cervical dysplasia in a pivotal Phase 3 registration study. After having both completion of commercial device design for the drug as well as manufacturing process development efforts underway, the drug maker is in prep mode for submitting the final package to the FDA in the upcoming weeks, with full expectation for first dosing to commence by fourth quarter.

    Management has also discussed that this Phase 3 trial will likely enroll around 350 patients at 150 sites worldwide, with a similar efficacy endpoint to that in the Phase 2 study. Selvaraju comments, “This is encouraging news, in our view, together with the fact that it has been 1.5 years since 160 patients received their first dosing of VGX-3100 in the Phase 2 study and no significant adverse events have been observed thus far.”
    Another positive factor weighing in INO’s corner is the presentation of a new plan called Inovio Vision 2020, set to have three drug candidates ready for registration in 2020. Of course, not at all surprising to the analyst, the first candidate ready will be VGX-3100. The second one will be a cancer-treating candidate, potentially new candidate, INO-5400, a multi-antigen immunotherapy to be used in combination with checkpoint inhibitors.

    Meanwhile, Inovio’s PENNVAX®-GP HIV immunotherapy is set to deliver Phase 1 data by 1H 2017. Selvaraju believes, “These data readouts in the coming quarters could drive further upside in the stock, in our view.”

    Additionally, Inovio’s total revenue for the quarter was $6.2 million, above Selvaraju’s projection, which the analyst attributes to a surge in development payments from the firm’s DARPA Ebola grant. The company saw a net loss of $18.7 million during the quarter, or ($0.26) per share.

    TipRanks analytics exhibit INO as a Strong Buy. Based on 4 analysts polled in the last 3 months, 3 rate a Buy on the stock and 1 maintains a Hold. The consensus price target stands at $17.50, marking a 97% upside from where the shares last closed.

  • garysnoop1 by garysnoop1 Aug 9, 2016 5:12 PM Flag

    Inovio Pharmaceuticals Inc. (NASDAQ:INO) has been assigned a $18.00 target price by equities research analysts at Brean Capital in a report released on Monday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Brean Capital’s price target indicates a potential upside of 92.51% from the stock’s previous close.
    Inovio Pharmaceuticals (NASDAQ:INO) traded down 3.64% on Monday, hitting $9.01. 1,746,943 shares of the stock were exchanged. The company’s 50 day moving average is $9.44 and its 200 day moving average is $8.78. Inovio Pharmaceuticals has a 1-year low of $4.50 and a 1-year high of $11.69. The stock’s market cap is $658.60 million.

    Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.05. During the same period in the previous year, the business earned ($0.09) EPS. The business had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $4.95 million. The firm’s revenue was up 17.0% on a year-over-year basis. On average, equities research analysts expect that Inovio Pharmaceuticals will post ($0.75) earnings per share for the current year.

    In related news, Director Morton Collins bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The shares were acquired at an average price of $9.13 per share, with a total value of $91,300.00. Following the completion of the transaction, the director now owns 142,291 shares of the company’s stock, valued at approximately $1,299,116.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Simon X. Benito sold 6,250 shares of the business’s stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $10.37, for a total transaction of $64,812.50. Following the transaction, the director now directly owns 24,048 shares in the company, valued at approximately $249,377.76. The disclosure for this sale can be found here.

    A number of large investors have made changes to their positions in INO. Creative Planning raised its stake in shares of Inovio Pharmaceuticals by 10.6% in the first quarter. Creative Planning now owns 170,599 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 16,400 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Inovio Pharmaceuticals by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 13,492 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 1,855 shares during the period. Bellevue Group AG acquired a new stake in shares of Inovio Pharmaceuticals during the first quarter valued at about $2,308,000. BlackRock Group LTD raised its stake in shares of Inovio Pharmaceuticals by 71.1% in the first quarter. BlackRock Group LTD now owns 22,064 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 9,168 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Inovio Pharmaceuticals by 10.3% in the first quarter. Geode Capital Management LLC now owns 481,434 shares of the biopharmaceutical company’s stock valued at $4,193,000 after buying an additional 44,923 shares during the period.

    A number of other analysts have also recently weighed in on INO. Maxim Group restated a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 21st. Rodman & Renshaw restated a “buy” rating and issued a $17.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 21st. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 21st. Stifel Nicolaus restated a “buy” rating and issued a $13.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 9th. Finally, Vetr upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.54 price objective for the company in a research note on Tuesday, April 12th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.39.

    Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

  • Zika virus now becomes a global threat moving geographically, and the number of infected people increases day by day

    Published By: Myrna Salomon on August 9, 2016 02:36 pm EST

    The threat of Zika virus has opened a new window for the pharmaceutical companies to enter into a lucrative market of vaccine production. The virus originally got hype from Brazil and has now spread its wings to approximately 42 countries belonging to South America, Central America and parts of the Caribbean.




    The virus can develop central nervous system diseases such as microcephaly, a condition in which the newborn has small head with lack of developmental abilities. With the spread of the disease, the health agencies became active and are now working diligently on multiple aspects to stop the invasion of the virus in other countries. President Barack Obama calls for an aid of $1.8 billion from Congress for the emergency measures to manage the epidemic. On the other hand, Congress has allocated a little amount initially to start the research and development of vaccine.

    World Health Organization has been in touch with 15 drug makers in order to develop Zika vaccine among which Sanofi SA (ADR) (NYSE:SNY) and GlaxoSmithKline plc (ADR) (NYSE:GSK) are playing major role in the development of the vaccine.

    VACCINE PRODUCTION

    Inovio Pharmaceuticals Inc (NASDAQ:INO) has been working on the development of the vaccine since December 2015. The DNA origin vaccine is expected to block the virus growth. The company is using clinical data of dengue vaccine. The vaccine is undergoing clinical trials and results are expected in the near future

  • Reply to

    Inovio Pharmaceuticals (INO).Brazil

    by garysnoop1 Aug 9, 2016 8:47 AM
    garysnoop1 garysnoop1 Aug 9, 2016 8:49 AM Flag

    the list of stocks in the Analyst Blog. INO featured..

    Sentiment: Strong Buy

  • Chicago, IL – August 08, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Companhia de Saneamento Basico do Estado de Sao Paulo (SBS), Cemig (CIG), iShares MSCI Brazil ETF ( EWZ) and Inovio Pharmaceuticals (INO).

  • JPMorgan Chase & Co. raised its stake in Inovio Pharmaceuticals by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 13,492 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 1,855 shares in the last quarter. Legal & General Group Plc raised its stake in Inovio Pharmaceuticals by 10.0% in the first quarter. Legal & General Group Plc now owns 13,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,205 shares in the last quarter. Strs Ohio bought a new stake in Inovio Pharmaceuticals during the second quarter worth $151,000. BlackRock Group LTD raised its stake in Inovio Pharmaceuticals by 71.1% in the first quarter. BlackRock Group LTD now owns 22,064 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 9,168 shares in the last quarter. Finally, LPL Financial LLC raised its stake in Inovio Pharmaceuticals by 65.8% in the first quarter. LPL Financial LLC now owns 22,222 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 8,822 shares in the last quarter.

  • All they needed to do was to copy Google if they couldn't think of something on their own..Example: Where is the mic..hello! ...build everything you can build around it..Oh.. and throw in a little inovation...make the mic the head of the octopus and build all things you can around it.Now, lets look at whats been done..Very sad they get paid for what they see others do..

  • Every where I go in Yarag,it breaks down..Tells a lot about VZ....run VZ run !!

  • garysnoop1 garysnoop1 Aug 3, 2016 1:32 PM Flag

    It goes a lot deeper than that..News came out after the fact..

  • garysnoop1 garysnoop1 Aug 3, 2016 12:07 PM Flag

    Ya Al..No PR..no support of any kind,no respect for stock (or bag holders,)I'm starting to worry myself.Bernie and the powers to be don't understand that credability is the foundation for all moves foward..NOT statements like low hanging fruit,where did that go..
    They had better step up and ketch us up before people have had enough and this goes back to 5 bucks.Not because of product potential but from corporate lack luster performance.. ...

    Sentiment: Hold

  • garysnoop1 garysnoop1 Aug 3, 2016 11:51 AM Flag

    Yup..and good luck to you..we will need it..

  • I wish I could be a untouchable insider..I don't mind getting rich by cheating..(get it?)

  • Reply to

    INO The Biggest Farce On Earth!!!!

    by golf.paul123 Jul 29, 2016 10:17 AM
    garysnoop1 garysnoop1 Jul 30, 2016 11:39 PM Flag

    I just love the way the price comes up.I it's tricking me into getting rich!!

  • Reply to

    Stairway to Heaven

    by dwkrl Jul 23, 2016 11:53 AM
    garysnoop1 garysnoop1 Jul 23, 2016 5:18 PM Flag

    Is there any wonder !

    Sentiment: Strong Buy

  • Reply to

    MESSAGE BOARD

    by pissedoffretiree Jul 21, 2016 3:36 PM
    garysnoop1 garysnoop1 Jul 23, 2016 8:57 AM Flag

    I have 2 icons on my desktop with the old path in it.I click back and forth ,some times it takes me there and sometimes it dosent.Thats how I just got here .gl

  • Reply to

    VZ buyiny another broken down ill run dud..

    by garysnoop1 Jul 23, 2016 8:38 AM
    garysnoop1 garysnoop1 Jul 23, 2016 8:41 AM Flag

    VZ.....please buy a up and commer,NOT one the sun is setting on. Think about it,which dot dom has ever been reserected..AOL,MY SPACE..none..

    Sentiment: Strong Sell

  • Worst run...excuse me,it dosen't run or haven't you seen the message boards..oh and where is the mic in search engine..not even smart enough to copy one of googles best assets...sad

  • Reply to

    Verizon buying this broken down looser!

    by garysnoop1 Jul 23, 2016 8:23 AM
    garysnoop1 garysnoop1 Jul 23, 2016 8:27 AM Flag

    Worst run...excuse me,it dosen't run or haven't you seen the message boards..oh and where is the mic in search engine..not even smart enough to copy one of googles best assets...sad

YIPI
0.79+0.04(+5.33%)Aug 26 2:44 PMEDT